188 related articles for article (PubMed ID: 34536094)
1. Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
González-Sales M; Djebli N; Meneses-Lorente G; Buchheit V; Bonnefois G; Tremblay PO; Frey N; Mercier F
Cancer Chemother Pharmacol; 2021 Dec; 88(6):997-1007. PubMed ID: 34536094
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
[TBL] [Abstract][Full Text] [Related]
3. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
4. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
7. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
8. Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
Djebli N; Buchheit V; Parrott N; Guerini E; Cleary Y; Fowler S; Frey N; Yu L; Mercier F; Phipps A; Meneses-Lorente G
Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):779-791. PubMed ID: 34495458
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Parrott N; Stillhart C; Lindenberg M; Wagner B; Kowalski K; Guerini E; Djebli N; Meneses-Lorente G
AAPS J; 2020 May; 22(4):78. PubMed ID: 32458089
[TBL] [Abstract][Full Text] [Related]
10. Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Meneses-Lorente G; Guerini E; Mercier F; Parrott N; Kowalski K; Chow-Maneval E; Buchheit V; Bergthold G; Fox E; Phipps A; Djebli N
Cancer Chemother Pharmacol; 2023 Mar; 91(3):239-246. PubMed ID: 36884068
[TBL] [Abstract][Full Text] [Related]
11. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
Osman HM; Tuncbilek M
Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
[TBL] [Abstract][Full Text] [Related]
12. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
[TBL] [Abstract][Full Text] [Related]
13. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
14. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
[TBL] [Abstract][Full Text] [Related]
15. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract][Full Text] [Related]
17. Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487
[TBL] [Abstract][Full Text] [Related]
18. Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Seo SW; Han DG; Choi E; Park T; Byun JH; Cho HJ; Jung IH; Yoon IS
Biomed Pharmacother; 2022 Feb; 146():112520. PubMed ID: 34902744
[TBL] [Abstract][Full Text] [Related]
19. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
20. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
